J.P. Morgan Healthcare Conference

Rob Michael

Vice Chairman, Finance and Commercial Operations
Chief Financial Officer

January 11, 2022
Forward-Looking Statements and Non-GAAP Financial information

Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on AbbVie’s operations, results and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits of the Allergan acquisition, failure to effectively integrate Allergan's businesses, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

This presentation contains GAAP and certain non-GAAP financial measures. Non-GAAP financial measures are adjusted for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses and other specified items presented in AbbVie’s reconciliation tables. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available in the appendix to this presentation and on the company’s website at www.abbvieinvestor.com.

Today’s discussions and presentation are intended for the investor community only; materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.
AbbVie is a Diversified Biopharmaceutical Company with Multiple Sources of Growth and Strong Long-term Outlook

<table>
<thead>
<tr>
<th>Immunology</th>
<th>Hematologic Oncology</th>
<th>Neuroscience</th>
<th>Aesthetics</th>
<th>Eye Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best-in-Class medicines position AbbVie for sustained leadership; Significant growth potential for new assets</td>
<td>Strong leadership position; Building a broad pipeline across a range of blood cancers for sustainable long-term growth</td>
<td>Positioned for significant growth with attractive commercial opportunities across Migraine, Psychiatry Neuro-Degeneration</td>
<td>Leadership positions across core Aesthetics areas; New products, global expansion and increasing penetration expected to drive significant long-term growth</td>
<td>Large franchise with investment opportunities to sustain eye care leadership and drive growth with internal and external innovation</td>
</tr>
</tbody>
</table>

Following U.S. Humira LOE in 2023, expect modest top-line growth in 2024 and return to strong top-line growth in 2025, with high-single digit CAGR through remainder of decade
A Unique Investment Opportunity Well Positioned For Continued Strong Shareholder Returns

Compelling capital allocation philosophy, balanced between supporting growth and returning capital to shareholders

• Strong operating cash flow to support investments for growth, return of cash to shareholders and rapid debt repayment

• Continued R&D investment in promising, innovative science across each of our therapeutic categories, as well as capacity to pursue additional mid- to late-stage pipeline assets to augment the internal pipeline

• Committed to a robust and growing dividend; Increased quarterly dividend by >250% since inception
Strong Financial Execution Since Inception as an Independent Company

Adjusted Net Revenues ($ in billions)

- 2013: $18.8
- 2014: $19.9
- 2015: $22.8
- 2016: $25.6
- 2017: $28.2
- 2018: $32.7
- 2019: $33.3
- 2020: $45.8
- 2021: $56.2

14.7% CAGR

Adjusted EPS

- 2013: $3.14
- 2014: $3.32
- 2015: $4.29
- 2016: $4.82
- 2017: $5.60
- 2018: $7.91
- 2019: $8.94
- 2020: $10.56
- 2021: $12.65

19.0% CAGR

Met or exceeded both total revenue and adjusted EPS guidance in all 35 quarters since becoming an independent company

*Based on FY21 guidance provided on 3Q21 earnings call. AbbVie issued sales guidance of approximately $56.2B and adjusted EPS guidance of $12.63 to $12.67.
On Track To Meet or Exceed Allergan Transaction Financial Commitments

- Generate >$2B in Synergies and Cost Savings in Year 3
  - Expect $1.8B in expense synergies in 2021
  - On track to achieve >$2B in 2022

- 10% Accretion Over the First Full Year of Combination, Peaking at >20%
  - Accretion meaningfully exceeded 10% in the first year following the Allergan acquisition
  - On track to deliver >20% peak accretion

- Reduce debt by $15B-$18B before end of 2021, with further deleveraging through 2023
  - Repaid $17B of combined company debt through the end of 2021
  - Expect to achieve net leverage ratio of ~2.0x by the end of 2022

✓ On-Track
Immunology

Transformed Immunology From a Single Product with Humira to a Portfolio Of Differentiated Therapies with the Addition of Skyrizi and Rinvoq

Expect combined risk-adjusted global sales of >$15 billion for Rinvoq and Skyrizi in 2025, with combined peak sales for Rinvoq and Skyrizi expected to exceed Humira peak revenues.

- $6.0B PsO + PsA
- $1.5B IBD
- $3.5B RA
- $1.7B AD
- $1.0B SpA
- $1.3B IBD

International markets expected to contribute sales of ~$4.5B for Skyrizi and Rinvoq based on strong labels in approved indications and outstanding launches across indications.

2019
- $0.4B

2020
- $2.3B
  - $0.7B
  - $1.6B

2021 Guidance
- ~$1.7B
- ~$2.9B
- ~$4.6B

2025 Guidance
- >$7.5B
- >$15B

2025 Guidance
Immunology

Pipeline of Novel Therapies to Improve Clinical Performance Across Rheumatology, Dermatology and Gastroenterology

<table>
<thead>
<tr>
<th><strong>ABBV-154</strong></th>
<th><strong>ABBV-157</strong></th>
<th><strong>ABBV-668</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-TNF Steroid Antibody Drug Conjugate</strong></td>
<td><strong>Small Molecule RoRγT Inverse Agonist</strong></td>
<td><strong>Small Molecule RIPK1 Inhibitor</strong></td>
</tr>
<tr>
<td>• Novel approach to target immunomodulation without steroid adverse effects</td>
<td>• Potential to more effectively inhibit IL-17 production than antagonist approaches</td>
<td>• Differentiated approach to modulating inflammation by inhibiting RIPK1 and inflammatory cytokine production</td>
</tr>
<tr>
<td>• Designed to provide transformational efficacy in AbbVie’s core indications</td>
<td>• Promising activity in Phase 1 study in psoriasis patients</td>
<td>• Potential to prevent necroptosis and reduce TLR4-driven inflammation to benefit patients with immune-mediated diseases (e.g. UC, CD, PsO)</td>
</tr>
<tr>
<td>• Currently in Phase 2b dose-ranging study in RA and Phase 2 in CD, PMR</td>
<td>• Phase 2b dose-ranging study initiated Q4 2021</td>
<td>• Expect to begin Phase 2 studies in 2022</td>
</tr>
</tbody>
</table>
Oncology

Established a Strong Leadership Position in Hematologic Oncology with Imbruvica and Venclexta

- Gold standard in CLL and preferred treatment for MCL and WM
- Most comprehensive efficacy and safety data in the BTK inhibitor class, with six positive Phase 3 CLL studies demonstrating superiority over all standard-of-care chemotherapy-based regimens
- Unmatched body of data showing sustained disease control and survival benefit will enable Imbruvica to maintain a strong competitive position

- 6 FDA Breakthrough Therapy designations and 4 approved indications across CLL and AML populations
- Nearing completion of registrational programs in MM and MDS
- Potential to become a foundational therapy in multiple hematologic malignancies, allowing patients to achieve more durable, deeper responses, including the option for some patients to stop treatment
# Oncology

Building a Broader, Deeper Pipeline to Address Significant Unmet Need in Oncology and Position Franchise for Sustainable Long-Term Growth

<table>
<thead>
<tr>
<th>Navitoclax</th>
<th>Epcoritamab</th>
<th>ABBV-383</th>
<th>Teliso-V</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BCL-2 / BCL-xL Inhibitor</strong></td>
<td><strong>CD3-CD20 Bispecific</strong></td>
<td><strong>BCMA-CD3 Bispecific</strong></td>
<td><strong>c-Met ADC</strong></td>
</tr>
<tr>
<td>- Current myelofibrosis therapies provide symptom relief, with minimal impact on underlying course of the disease</td>
<td>- Encouraging early clinical data demonstrate competitive ORR/CR in DLBCL and FL, with manageable safety profile</td>
<td>- Emerging clinical data demonstrate potential to provide best-in-class efficacy and safety across lines of therapy in MM</td>
<td>- Teliso-V granted Breakthrough Therapy Designation based on promising Phase 2 data in 2L+ non-squamous NSCLC patients with wild-type EGFR and overexpressed c-Met (~25% of non-sq. NSCLC population)</td>
</tr>
<tr>
<td>- Encouraging Phase 2 data demonstrates potential for anti-fibrosis activity to deliver significant reductions in bone marrow fibrosis and durable clinical improvements</td>
<td>- Potential to be a best-in-class CD3-CD20 bispecific across B cell malignancies, e.g. DLBCL and FL</td>
<td>- Expect to begin Phase 3 studies in relapsed/refractory MM in 2022</td>
<td>- Next-generation c-Met ADC utilizing a topoisomerase inhibitor payload (ABBV-400) in Phase 1, with potential to provide deeper responses with broader applicability</td>
</tr>
<tr>
<td>- Pivotal trial readouts, regulatory submission and approval anticipated in 2023</td>
<td>- Phase 3 ongoing in relapsed/refractory DLBCL and additional Phase 3 studies to begin in 2022; Phase 2 expansion cohorts ongoing in DLBCL and FL, with potential to support regulatory submission in 2H 2022</td>
<td></td>
<td>- Longer-term Phase 2 Teliso-V data expected in 2023, with potential to support accelerated approval</td>
</tr>
</tbody>
</table>

---

*Note: Not for promotional use*
Neuroscience

Building a Leading Portfolio with Options for Every Patient Across the Migraine Spectrum

**Acute Migraine Treatment**
- #1 prescribed branded acute treatment for migraine
- Rapid share uptake and broad commercial access
- **Expect >$1B in peak sales**

**Episodic Migraine Prevention**
- Only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine
- Strong efficacy data and favorable safety profile demonstrated in robust clinical development program
- Encouraging early launch trends and growing market access
- Potential expansion into chronic migraine prevention (Phase 3 ongoing)
- **Expect >$1B in peak sales**

**Chronic Migraine Prevention**
- Unique foundational treatment for prevention of chronic migraine
- Branded leader in new patient starts
- Potential expansion into episodic migraine (Phase 3 ongoing)

*Based on IQVIA cumulative TRx data through 12/24/21*
Neuroscience

Significant Growth Opportunities in Psychiatry and Neuro-Degeneration

- A versatile atypical antipsychotic that provides strong efficacy across multiple symptoms, with minimal impact on weight, lipids and fasting blood glucose
- Expect Vraylar peak sales to approach $4B with current approved indications (schizophrenia, bipolar I disorder, bipolar depression)
- Expect to submit regulatory application 1H 2022 as an adjunctive treatment of major depressive disorder which, if approved, would represent a significant opportunity for Vraylar

Advancing A Transformative Pipeline For Parkinson’s and Alzheimer’s Diseases

- ABBV-951: Nearing completion of registrational program for subcutaneous levodopa/carbidopa delivery system with approvals anticipated in early 2023; Potentially transformative improvement to current treatment options for patients with advanced Parkinson’s disease. Expect ABBV-951 to reach peak sales of >$1B
- Early-Stage Programs in Alzheimer’s Disease: Focused on optimized a-beta antibody approaches for faster amyloid clearance with low ARIA and patient friendly dosing regimen, as well as clearing intracellular tau aggregates and modulating neuroinflammatory response
Aesthetics

Market Leader in Global Aesthetics with Significant Growth Opportunities from New Product Introduction, Global Expansion and Increasing Market Penetration

Increased Investments Driving Strong Growth

- Increased investments to retain existing patients, activate new consumers, train injectors and help our customers grow their practices
- Enhanced and more consistent promotional spending
- Enhanced digital products and services for patients and providers through Allē platform
- Expanding footprint and resources in major global markets

Accelerating R&D Programs & Strengthening Pipeline with Business Development

- Innovative Toxins: Short-acting and long-acting toxins both in Phase 2 development
- Novel Dermal Fillers: Bio-stimulatory and regenerative fillers, HArmonyCa filler
- Body Contouring: Next-gen CoolSculpting, CoolTone, Soliton for cellulite

Aesthetics Franchise Positioned for Sustainable Long-term Growth

- Expect high-single digits revenue CAGR for Aesthetics business through 2029, substantially higher than previous expectations for mid-single digit growth at the time of the Allergan transaction announcement
- Expect Aesthetics sales of >$9B in 2029
Eye Care

$3.5 billion Franchise with Investment Opportunities to Sustain Eye Care Leadership and Drive Growth with Internal and External Innovation

Maximize Current Portfolio in Glaucoma and Dry Eye

- Multiple leading brands to help preserve and protect vision
- Highly profitable businesses that generate significant cash flow for future investment

Develop Novel Products to Support Long-Term Growth

- Successfully launch Vuity, the first FDA-approved eye drop to treat presbyopia
- Establish a strong position in retinal diseases with longer duration delivery technology such as RGX-314, a potential one-time gene therapy for wet AMD, diabetic retinopathy and other chronic retinal conditions
- Build a novel pipeline to address significant unmet needs in large, growing Eye Care markets
Innovation-Driven R&D Organization

Proven Track Record of Developing New Medicines That Consistently Elevate the Standard of Care

- 185+ Clinical Trials
- 5 Core Therapeutic Areas
- 11K+ R&D Employees
- $6.7B Annual R&D Investment*
- $2.0B Annual Business Development Allocation
- 80+ Clinical Programs
- ~50 New Molecular Entities
- 40+ Conditions Treated
- 21 Major Product or Indication Approvals**
- 65+ New Study Starts Planned for 2022

*Based on FY21 guidance provided on 2Q21 earnings call for non-GAAP R&D expense.
**Reflects approvals since 2013
AbbVie Pipeline

As of January 11, 2022
Excludes devices in development
*Partnered assets; See appendix for partnership summary
Not for promotional use

**Phase 1**
- ABBV-668 (RIPK1) Multiple Immunology Diseases
- ABBV-151 (GARP+TGFβ1) Solid Tumors
- ABBV-155 (BCL-xL ADC) Solid Tumors
- ABBV-400 (CD5 ADC) NSCLC
- ABBV-181 (PD-1) Solid Tumors
- ABBV-621 (TAILR) Solid/Heme Tumors
- ABBV-744 (BET) MF
- ABBV-927 (CD40) Solid Tumors
- ABBV-647* (PTK7 ADC) NSCLC
- ABBV-011 (SE26 ADC) SCLC
- ABBV-637 (EGFR BCL-xL ADC) NSCLC
- Venclexta (BCL-2) ALL
- CCW702* (CD33) Heme Tumors
- NAV-030* (CD3) Solid Tumors
- HSN-3086* / JAB-241622 (Alpha2) Presbyopia
- ALPN-0605* (alpha-Synuclein) PD
- AL003* (CD33) AD
- ABBV-CLS-7326* (aif2B) Multiple Neuro
- AGN-241622 (Alpha2) Presbyopia
- ABBV-1882 (anti-PDI/anti-a4b7) HIV

**Phase 2**
- ABBV-154 (TNF/-Steroid ADC) RA
- ABBV-154 (TNF/-Steroid ADC) PMR
- ABBV-154 (TNF/-Steroid ADC) CD
- ABBV-599 (BTK/JAK) SLE
- ABBV-157 (ROR-T) PsO
- Rinvoq (JAK 1) Vitiligo
- Acazicolcept
- CLBR001/SWI019* (sCAR T) Solid Tumors
- Elezanumab (RGMa) Stroke
- Elezanumab (RGMa) SCI
- AL002* (TREM2) AD
- BNT3 (SNARE) Glabellar Lines
- OnabotA X (SNARE) Glabellar Lines
- OnabotX (SNARE) Forehead Lines
- AGN-231688 (Chemokine) Dry Eye
- AGN-242428 (RORγ) Dry Eye
- RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- RGC-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma
- CF Triple Combo (CFTR-C1/CFTR-C2/CFTR-P)
- Armour Thyroid (T3/T4) Hypothyroidism
- AGN-151607 (SNARE) Atrial Fibrillation

**Registralional / Phase 3**
- Rinvoq (JAK 1) CD
- Rinvoq (JAK 1) GCA
- Skyrizi* (IL-23) UC
- Imbruvica* (BTK) 1L FL
- Imbruvica* (BTK) 1L MCL
- Imbruvica* (BTK) + Venclexta (BCL-2) R/R MCL
- Imbruvica* (BTK) R/R FL/MZL
- Imbruvica* (BTK) + Venclexta (BCL-2) 1L CLL
- Venclexta* (BCL-2) AML Maintenance
- Venclexta* (BCL-2) 1L CLL
- Venclexta* (BCL-2): MDS
- Navitoclax (BCL-2/BCL-xL) Myelofibrosis
- Epocitamab* (CD3-CD20): R/R DLBCL
- Telisimo-V* (CD5 ADC) NSCLC
- Veliparib (PARP) BRCA Breast Cancer
- Veliparib (PARP) 1L Ovarian Cancer
- ABBV-951 (dopamine receptor) PD
- Vraylar* (D2.5-HT1A, 5-HT2A) aMDD
- Quilda (CRGP) Chronic Migraine Prev.
- Botox (SNARE) Masseter Pneumone
- Botox (SNARE) Platysma Pneumone
- RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Aztreonam/Aivitabactam* (PBP3) Infection

**Submitted**
- Rinvoq (JAK 1) AD (US)
- Rinvoq (JAK 1) AS (US)
- Rinvoq (JAK 1) UC
- Rinvoq (JAK 1) nr-Axial SpA
- Skyrizi* (IL-23) PsA (US)
- Skyrizi* (IL-23) CD

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

Not for promotional use

J.P. Morgan Healthcare Conference | January 11, 2022
## Anticipated Key Pipeline Events

<table>
<thead>
<tr>
<th>Regulatory Approvals</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinvoq AD (US)</td>
<td></td>
<td>Rinvoq CD</td>
</tr>
<tr>
<td>Rinvoq AS (US)</td>
<td></td>
<td>Imbruvica + Venclexta R/R MCL</td>
</tr>
<tr>
<td>Rinvoq UC</td>
<td></td>
<td>Imbruvica + Venclexta R/R MCL</td>
</tr>
<tr>
<td>Rinvoq nr-Axial SpA</td>
<td></td>
<td>Imbruvica R/R FL/MZL</td>
</tr>
<tr>
<td>Skyrizi CD</td>
<td></td>
<td>Venclexta 3L+ MM w/ t(11;14)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regulatory Submissions</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinvoq CD</td>
<td></td>
<td>Skyrizi UC</td>
</tr>
<tr>
<td>Imbruvica + Venclexta 1L CLL</td>
<td></td>
<td>Venclexta 3L+ MM w/ t(11;14)</td>
</tr>
<tr>
<td>Imbruvica + Venclexta R/R MCL</td>
<td></td>
<td>Imbruvica 1L FL</td>
</tr>
<tr>
<td>Imbruvica R/R FL/MZL</td>
<td></td>
<td>Teliso-V NSCLC (submit for AA on Ph2 data)</td>
</tr>
<tr>
<td>Venclexta Higher Risk MDS (for AA on Ph1 data)</td>
<td></td>
<td>Navitoclax 1L and R/R MF</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ph3/Registrational Data Readouts</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinvoq Ph3 CD Induction/Maintenance</td>
<td></td>
<td>Skyrizi Ph3 UC Induction/Maintenance</td>
</tr>
<tr>
<td>Venclexta Ph3 3L+ MM t(11;14) (CANOVA)</td>
<td></td>
<td>Navitoclax Ph2 3L R/R MF</td>
</tr>
<tr>
<td>Imbruvica + Venclexta Ph3 R/R MCL (SYMPATICO)</td>
<td></td>
<td>Navitoclax Ph2 R/R MF</td>
</tr>
<tr>
<td>Imbruvica Ph3 R/R FL/MZL (SELENE)</td>
<td></td>
<td>Qulipta Chronic Migraine Prevention</td>
</tr>
<tr>
<td>Venclexta Ph1/2 Higher Risk MDS</td>
<td></td>
<td>BoNT E (Short-Acting Toxin) Glabellar Lines</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Early-Stage POC Data Readouts</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystic Fibrosis Triple Combo (C1/C2/P) Ph2</td>
<td></td>
<td>ABBV-154 (TNF-Steroid ADC) Ph2 CD Induction</td>
</tr>
<tr>
<td>ABBV-154 (TNF-Steroid ADC) Ph2 RA</td>
<td></td>
<td>ABBV-154 (TNF-Steroid ADC) Ph2 PMR</td>
</tr>
<tr>
<td>ABBV-599 (JAK/BTK) Ph2 SLE</td>
<td></td>
<td>ABBV-GMAB-3009 (CD37) Ph1 Heme Tumors</td>
</tr>
<tr>
<td>ABBV-647 (PTK7 ADC) Ph1 NSCLC</td>
<td></td>
<td>ABBV-GLS-578484 (PTPIN2) Ph1 Solid Tumors</td>
</tr>
<tr>
<td>ABBV-011 (SEZ6 ADC) Ph1 SCLC</td>
<td></td>
<td>ABBV-155 (BCL-xL ADC) Ph1 Solid Tumors *</td>
</tr>
</tbody>
</table>

As of January 11, 2022
AA = Accelerated Approval
*Early Oncology programs where monotherapy results did not warrant advancement; assets will continue to be evaluated in combination studies.
AbbVie: A Unique Investment Opportunity Poised for Continued Strong Shareholder Returns

- Portfolio of leading brands in attractive and sustainable markets
- Pipeline of innovative, highly differentiated assets to address significant unmet needs, with potential to drive significant growth
- Compelling capital allocation philosophy balanced between supporting growth and returning capital to shareholders
- Track record of strong execution, consistently meeting or exceeding financial commitments to deliver industry-leading financial performance

A unique investment vehicle, offering top-tier revenue and EPS growth, significant cash flow and strong return of capital to shareholders
GAAP to Non-GAAP Reconciliations

**Diluted earnings per share**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As reported (GAAP)</td>
<td>$2.56</td>
<td>$1.10</td>
<td>$3.13</td>
<td>$3.63</td>
<td>$3.30</td>
<td>$3.66</td>
<td>$2.72</td>
<td>$6.31</td>
<td></td>
</tr>
<tr>
<td>Adjusted for specified items:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquisition related costs</td>
<td>0.23</td>
<td>0.18</td>
<td>0.45</td>
<td>0.68</td>
<td>0.93</td>
<td>1.00</td>
<td>3.23</td>
<td>8.11</td>
<td>5.22</td>
</tr>
<tr>
<td>Separation costs</td>
<td>0.10</td>
<td>0.24</td>
<td>0.13</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Acquired in-process R&amp;D, milestones and other R&amp;D expenses</td>
<td>0.21</td>
<td>0.17</td>
<td>0.35</td>
<td>0.17</td>
<td>0.29</td>
<td>0.36</td>
<td>0.45</td>
<td>0.85</td>
<td>0.75</td>
</tr>
<tr>
<td>Calico collaboration</td>
<td>--</td>
<td>0.46</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>0.32</td>
<td>--</td>
</tr>
<tr>
<td>Stemcentrx-related impairment</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>2.66</td>
<td>0.56</td>
</tr>
<tr>
<td>Shire termination</td>
<td>--</td>
<td>1.12</td>
<td>0.10</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>U.S. tax reform repatriation tax</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>2.81</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Other impacts related to tax law change</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>0.12</td>
<td>(2.04)</td>
<td>(0.40)</td>
<td>--</td>
<td>(1.02)</td>
<td>--</td>
</tr>
<tr>
<td>Other</td>
<td>0.04</td>
<td>0.05</td>
<td>0.13</td>
<td>0.22</td>
<td>0.31</td>
<td>0.31</td>
<td>(0.58)</td>
<td>(0.10)</td>
<td>0.09</td>
</tr>
<tr>
<td>As adjusted (non-GAAP)</td>
<td>$3.14</td>
<td>$3.32</td>
<td>$4.29</td>
<td>$4.62</td>
<td>$5.60</td>
<td>$7.91</td>
<td>$8.94</td>
<td>$10.56</td>
<td>$12.65</td>
</tr>
</tbody>
</table>

Acquisition related costs primarily include intangible asset amortization, changes in the fair value of contingent consideration, and transaction, financing, and integration costs associated with acquisitions as well as amortization of acquisition date fair value step-up for inventory. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired in-process R&D, milestones and other R&D expenses primarily consist of upfront and milestone payments associated with R&D collaborations and licensing arrangements. Other primarily includes charges and resolutions of litigation matters, restructuring charges associated with streamlining global operations, tax audit settlements, charitable contributions, COVID-19 related expenses and the Reata divestiture.

**Net revenues**


Note: Based on company guidance as of October 29, 2021. Stated as mid-point of the estimated range of $6.29 to $6.33 (GAAP diluted EPS) and $12.83 to $12.67 (adjusted EPS, non-GAAP).
## AbbVie’s Partnered Assets

- **Imbruvica** jointly developed with Janssen Biotech
- **Venclexta** jointly developed with Roche
- **Skyrizi** developed in cooperation with Boehringer Ingelheim
- **Vraylar** developed in cooperation with Gedeon Richter
- **ABBV-0805** developed in cooperation with BioArctic
- **CCW702** developed by Scripps in a first-in-patient trial and AbbVie holds option for additional development
- **CLBR001/SWI019** developed by Calibr in a first-in-patient trial and AbbVie holds option for additional development
- **AL002/AL003** developed by Alector through Phase 2 and AbbVie holds option for additional development
- **TTX-030** developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global development
- **ABBV-2029** developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option for additional development
- **ABBV-647** developed in cooperation with Pfizer
- **Epocritamab/GEN3009** developed in partnership with Genmab
- **JAB-3068/3312** developed in partnership with Jacobio
- **HPN-217** developed by Harpoon through Phase 1/2 and AbbVie holds option for additional development
- **RGX-314** co-developed by REGENXBIO and AbbVie
- **ABBV-IMAB-TJC4** co-developed by I-Mab and AbbVie
- **ABBV-CLS-579/484/7262** co-developed by Calico and AbbVie
- **Acazicolcept (ALPN-101)** developed by Alpine Immune Sciences through current Phase 2 study and AbbVie holds option for additional development
- **Aztreonam/Avibactam** co-developed by Pfizer and AbbVie
- **Teliso-V** licensed from Seagen and Pierre Fabre